Central nervous system melanoma – Diagnostics – Overview of Information and Clinical Research

Diagnosing central nervous system melanoma requires specialized imaging and careful clinical evaluation to identify the presence of melanoma cells in the brain, spinal cord, or surrounding membranes. This complex process involves multiple tests to confirm the diagnosis, determine how far the disease has spread, and guide treatment decisions for patients and their medical teams.

Introduction: Who Needs Diagnostic Testing and When

Diagnostic testing for central nervous system melanoma is essential for anyone who has been diagnosed with melanoma and begins experiencing unusual symptoms related to the brain or nervous system. This becomes particularly important because melanoma has one of the highest tendencies among all cancers to spread to the brain and surrounding tissues. In fact, melanoma is the third most common cause of brain metastases, following only lung and breast cancer.^[1]

People with malignant melanoma should seek diagnostic testing if they develop neurological symptoms or behavioral changes that seem unusual or concerning. These symptoms might include persistent headaches, vision problems, difficulty with coordination or balance, unexplained confusion, or changes in personality. The symptoms occur because melanoma cells growing in the brain create pressure and inflammation around the affected areas. It’s worth noting that many patients don’t show symptoms initially, which is why regular monitoring is so important for those with advanced melanoma.^[8]

Certain groups of melanoma patients face higher risk and may need more frequent diagnostic checks. These include men over age 60, people with deep or ulcerated (broken skin surface) primary melanoma spots, those with more than three lymph nodes affected, anyone who already has melanoma in other organs at diagnosis, and individuals with specific genetic changes in their tumor cells called BRAF or NRAS mutations. People with elevated levels of a blood marker called lactate dehydrogenase or LDH also face increased risk.^[1]

⚠️ Important

Central nervous system metastases are increasingly detected at the asymptomatic stage through routine brain scans during follow-up appointments or when doctors are evaluating patients for systemic treatment. This means that even without symptoms, regular imaging can catch problems early, giving patients and doctors more treatment options and potentially better outcomes.

In advanced melanoma, about 50 to 60 percent of patients will eventually develop disease in the central nervous system, with roughly 75 percent of these cases involving multiple spots in the brain. Research shows that central nervous system metastases are found in about 7 percent of melanoma patients at the time of initial diagnosis, and autopsy studies reveal that approximately 75 percent of melanoma patients who die have evidence of brain involvement.^[9]

The latest staging system from the American Joint Committee on Cancer recognizes the serious nature of central nervous system involvement by classifying it as a separate category in stage IV disease, labeled M1d. This classification acknowledges that melanoma in the brain or spinal cord represents one of the most challenging complications and requires specialized diagnostic and treatment approaches.^[9]

Diagnostic Methods for Identifying Central Nervous System Melanoma

Brain Imaging Studies

The cornerstone of diagnosing central nervous system melanoma is brain imaging, which allows doctors to see inside the brain and spinal cord without surgery. Magnetic resonance imaging or MRI has become the standard imaging technique for detecting melanoma in the central nervous system. This test uses powerful magnets and radio waves to create detailed pictures of the brain’s soft tissues. Unlike regular x-rays, MRI doesn’t use radiation, making it safer for repeated use during ongoing monitoring.^[9]

When melanoma spreads to the brain, it often shows specific characteristics on MRI scans that help doctors identify it. The melanin pigment in melanoma cells has special magnetic properties that cause the tumor to appear bright on certain types of MRI images called T1-weighted sequences. On other imaging sequences called T2-weighted images, melanoma typically appears darker. These unique signal patterns help radiologists distinguish melanoma from other types of brain tumors or abnormalities.^[4]

A special type of MRI called contrast-enhanced MRI involves injecting a substance called gadolinium into a vein before the scan. This contrast material helps highlight areas where the normal protective barrier around blood vessels in the brain, called the blood-brain barrier, has broken down. Melanoma metastases typically show enhancement with gadolinium, appearing brighter on the scan and making them easier to detect. This technique is particularly helpful for finding small metastases that might otherwise be missed.^[4]

Computed tomography or CT scanning represents another imaging option, especially when MRI isn’t available or can’t be performed due to certain medical devices in a patient’s body. CT scans use x-rays and computer processing to create cross-sectional images of the brain. On CT, melanoma metastases typically appear as areas of equal or slightly higher density compared to normal brain tissue. The CT value, which measures tissue density, often ranges from 45 to 61 for melanoma lesions, reflecting the presence of melanin and sometimes blood within the tumors.^[4]

Cerebrospinal Fluid Analysis

When melanoma spreads to the membranes covering the brain and spinal cord, a condition called leptomeningeal metastases or leptomeningeal disease, examining the cerebrospinal fluid or CSF becomes crucial. This clear fluid bathes and cushions the brain and spinal cord, and it can be sampled through a procedure called a lumbar puncture or spinal tap. During this procedure, a doctor inserts a thin needle between vertebrae in the lower back to withdraw a small amount of fluid for testing.^[4]

Laboratory examination of cerebrospinal fluid can reveal the presence of melanoma cells floating in the fluid, confirming leptomeningeal involvement. Under the microscope, specialists look for abnormal cells with characteristics typical of melanoma, such as specific shapes, large nuclei with prominent internal structures called nucleoli, and sometimes visible melanin pigment. Finding melanoma cells in the cerebrospinal fluid provides definitive proof of leptomeningeal disease.^[4]

Cerebrospinal fluid analysis also provides information about the overall condition of the central nervous system. Doctors measure protein levels, glucose concentration, and white blood cell counts in the fluid. In patients with leptomeningeal metastases, protein levels are often elevated while glucose levels may be decreased, and there may be an increased number of white blood cells as the body responds to the cancer cells.^[4]

Physical and Neurological Examination

Before any imaging or laboratory tests, doctors perform a thorough physical and neurological examination. This hands-on assessment helps identify symptoms and signs that might indicate central nervous system involvement. The examination typically includes checking mental status, testing reflexes, evaluating muscle strength and sensation, assessing coordination and balance, and examining the eyes including pupil responses and eye movements.^[8]

Certain findings on neurological examination can suggest specific locations of melanoma in the brain. For instance, problems with eye movement might indicate a lesion near the nerves that control the eyes, while weakness on one side of the body could suggest involvement of the motor areas of the brain. Changes in mental function, personality, or behavior might point to involvement of the frontal lobes. Difficulty with balance or coordination often suggests problems in the cerebellum, the lower back part of the brain.^[8]

Additional Imaging Studies

Beyond standard brain imaging, doctors may order additional scans to evaluate the full extent of disease. Spinal MRI can detect melanoma spread to the spinal cord or the tissues surrounding it. Whole-body imaging with CT scans of the chest, abdomen, and pelvis helps identify melanoma in other organs, which is important for understanding the overall stage of disease and planning treatment.^[4]

Some centers use specialized nuclear medicine scans called PET scans (positron emission tomography) that can detect melanoma cells throughout the body based on their increased metabolic activity. While PET scans are less commonly used specifically for brain metastases due to high background activity in normal brain tissue, they can be valuable for detecting disease elsewhere in the body and sometimes for monitoring response to treatment.^[3]

Distinguishing Primary from Metastatic Disease

An important aspect of diagnosis involves determining whether melanoma in the central nervous system represents spread from a melanoma elsewhere in the body or is a rare primary central nervous system melanoma that originated directly in the brain or spinal cord tissues. Primary central nervous system melanoma is extremely uncommon, accounting for only about 1 percent of all melanoma cases and roughly 0.07 percent of all brain tumors.^[4]

To distinguish between these possibilities, doctors conduct a thorough examination of the entire body, particularly checking the skin for any suspicious moles or lesions that might represent the original melanoma. They also examine the eyes, as melanoma can originate in the pigmented layer of the eye called the uvea. A complete medical history helps identify any previous melanoma diagnoses or suspicious skin lesions that may have been removed in the past.^[2]

Primary central nervous system melanoma typically arises from melanocytes that naturally exist in the leptomeninges, the membranes covering the brain and spinal cord. These tumors are usually darkly pigmented solid masses and often occur in the perimedullary region (around the spinal cord) or high cervical area (upper neck region). On microscopy, they show sheets of abnormal cells with prominent nucleoli and frequent cell divisions, and they often invade into the surrounding brain tissue.^[2]

Diagnostic Testing for Clinical Trial Enrollment

When patients with central nervous system melanoma consider participating in clinical trials testing new treatments, they typically need to undergo additional diagnostic evaluations beyond those used for standard diagnosis. These tests help researchers ensure that participants meet specific criteria for the study and provide baseline measurements that can be compared to results after treatment.^[3]

Most clinical trials require recent brain imaging, usually MRI scans performed within a specific timeframe before enrollment, often within four weeks. These baseline scans document the exact number, size, and location of melanoma metastases in the brain. Researchers measure each lesion carefully, often in three dimensions, to calculate total tumor volume. This detailed measurement allows precise assessment of whether tumors shrink, stay stable, or grow during the trial.^[3]

Clinical trials often categorize patients based on whether they have symptoms from their brain metastases. This distinction is important because symptomatic and asymptomatic patients may respond differently to treatments. Symptomatic patients might have headaches, seizures, weakness, or cognitive changes requiring medications like steroids to reduce brain swelling. Trials may include only one group or compare outcomes between symptomatic and asymptomatic patients.^[11]

Blood tests form another crucial component of trial eligibility screening. These typically include complete blood counts to ensure adequate numbers of red blood cells, white blood cells, and platelets. Researchers also check liver and kidney function through tests measuring enzymes and waste products in the blood. The lactate dehydrogenase or LDH level, which often increases with melanoma progression, is commonly measured. Some trials require specific LDH ranges for participation.^[1]

Genetic testing of tumor tissue has become increasingly important for clinical trial enrollment. Many trials specifically target patients whose melanoma has certain genetic mutations. The BRAF gene mutation, found in about 40 to 50 percent of melanomas, represents the most commonly tested alteration. Researchers obtain tumor tissue through biopsy or from previous surgical specimens to perform this testing. Some trials focus exclusively on BRAF-positive patients, while others enroll only BRAF-negative cases.^[1]

⚠️ Important

Patients who have received previous local treatments for brain metastases, such as surgery or radiation therapy, may still be eligible for clinical trials. However, trials vary in whether they accept patients with previously treated brain lesions. Some studies specifically enroll only patients with newly diagnosed, untreated brain metastases, while others welcome those who have had prior local therapy but developed new or progressing disease. Always discuss your complete treatment history with the trial team to determine eligibility.

Performance status assessment represents another standard requirement for trial participation. Doctors use scoring systems like the Eastern Cooperative Oncology Group scale to rate how well patients can perform daily activities. This score ranges from 0 (fully active, no restrictions) to 4 (completely disabled, bedridden). Most trials require patients to have relatively good performance status, typically scores of 0, 1, or sometimes 2, ensuring they are healthy enough to tolerate experimental treatments.^[3]

Some trials investigating new therapies for leptomeningeal disease require cerebrospinal fluid sampling not just for diagnosis but also for monitoring treatment response. Researchers may collect cerebrospinal fluid at multiple timepoints during the trial to look for changes in the number of cancer cells, measure levels of specific proteins or biomarkers, or assess drug concentrations in the fluid. This helps scientists understand how well treatments penetrate into the cerebrospinal fluid and affect melanoma cells there.^[4]

Clinical trials often require documentation of the size and number of brain metastases according to specific criteria. Many studies use the Response Evaluation Criteria in Solid Tumors, commonly called RECIST criteria, or modified versions adapted for brain tumors. These standardized measurement approaches ensure consistent evaluation of tumor response across different patients and research centers. Baseline imaging establishes measurable target lesions that will be followed throughout the trial.^[3]

For patients considering trials of combination therapies involving both local brain treatments and systemic drugs, coordination between different specialists becomes essential. Neurosurgeons, radiation oncologists, and medical oncologists work together to determine the optimal sequence and timing of different interventions. Diagnostic imaging before and after local treatments helps guide these decisions and assess eligibility for subsequent systemic therapy trials.^[11]

Prognosis and Survival Rate

Prognosis

The outlook for patients with central nervous system melanoma depends on multiple factors including the number and size of brain metastases, whether symptoms are present, overall health status, and what treatments are received. Detection of lesions in the central nervous system is associated with poor prognosis overall. Central nervous system metastases lead to death in 20 to 50 percent of patients, and symptomatic lesions are the immediate cause of death in about 90 percent of patients who die from melanoma with brain involvement.^[9]

Certain factors are associated with better outcomes. Patients who receive both local treatments directed at brain metastases and effective systemic therapies tend to survive longer than those who receive systemic treatment alone. The type of systemic treatment also matters significantly, with newer immunotherapy and targeted therapy approaches offering improved outcomes compared to older chemotherapy regimens.^[11]

The development of brain metastases typically occurs within the first three years after melanoma surgery in patients with stage III disease, with about 15 percent of these patients eventually developing brain involvement. Most brain metastases are located in the upper part of the brain (supratentorial), with approximately 15 percent occurring in the lower parts (infratentorial).^[1]

Survival Rate

According to historical data from before newer treatments became available, median overall survival after central nervous system metastasis diagnosis was approximately 5 to 7 months. In symptomatic patients undergoing whole brain radiotherapy, which is now rarely used as first-line treatment, median overall survival was only 2 to 5 months. Patients undergoing surgery or stereotactic radiotherapy had median survival roughly twice as long.^[9]

More recent data from centers using modern treatments show improved outcomes. In one study of 70 patients with melanoma brain metastases, the median overall survival for all patients was 10.2 months. Among patients treated with local therapies, those who had surgical resection alone had a median survival of 10 months, while those who received both resection and stereotactic radiosurgery had median survival of 17.3 months. Patients treated with stereotactic radiosurgery alone had median survival of 17.4 months.^[11]

The volume of disease treated also impacts survival. Patients who had less than 2 cubic centimeters of tumor volume treated had better median overall survival of 20.5 months compared to 12 months for those with more than 2 cubic centimeters treated. The type of systemic therapy received significantly influenced outcomes as well. Patients treated with dual immunotherapy combining two types of immune checkpoint inhibitors had the best median overall survival at 26.7 months, compared to 14.1 months for single-agent anti-PD-1 immunotherapy, 14.3 months for ipilimumab alone, and 10.9 months for kinase inhibitors targeting BRAF mutations.^[11]

Patients who did not receive central nervous system-directed local treatment had particularly poor outcomes, with median overall survival of only 1.2 months. This emphasizes the importance of combining local brain-directed therapies with effective systemic treatments for optimal outcomes.^[11]

For patients with leptomeningeal metastases from central nervous system melanoma, prognosis is extremely poor. In one reported case, a patient who received aggressive treatment consisting of concurrent radiotherapy and weekly chemotherapy injected into the cerebrospinal fluid, followed by monthly maintenance chemotherapy, survived 13 months after diagnosis. However, leptomeningeal metastasis from solid tumors like melanoma generally has a very poor outlook, and current treatments are largely palliative rather than curative.^[4]

#1 Clinical Trials Search in Europe